1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Longitudinal FDG-PET studies on at-risk subjects
Study N Decline Baseline Clinical Characteristics^* FU Method
Age (yr) M MMSE Ed
Chételat et al, 2003¹⁰ 17/7 MCI to AD 69.9 (6.7) 47.1 27.2 (1.3) NA 18 SPM
Anchisi et al, 2005¹¹ 48/14 aMCI to AD 67.7 (8.3) 50.7 27.7 (1.7) 11.0 (4.7) 12 SPM
Arnaiz et al, 2001¹² 20/11 MCI to AD 62.7 (8.5) 60.0 26.9 (2.3) 11.6 (2.1) 36.8 rCMRGlu
Mosconi et al, 2004¹³ 37/8 aMCI to AD 67.1 (7.7) 45.9 28.0 (1.5) 9.6 (4.7) 12.0 SPM
Drzezga et al, 2005¹⁴ 30/12 MCI to AD 70.4 (7.8) 46.7 26.9 (1.9) 11.6 (3.4) 15 NEUROSTAT
Silverman et al, 2003¹⁵ 128/82 MCI to D 66 49.1 24 (6.4) NA 34.8 NA
Note:—aMCI indicates amnestic MCI; N, number of patients analyzed/number of conversions; M, % of male subjects; Ed, years of education; FU, mean follow-up time in months; D, dementia; SPM, statistical parametric mapping; rCMRGlu, regional cerebral glucose metabolic rates; NEUROSTAT, neurological statistical image analysis software; NA, not available; FDG-PET, fluorodeoxyglucose–positron-emission tomography.
* Each cell was listed as mean value (SD).